论文部分内容阅读
本文报告了抗矽口服液对大鼠实验性矽肺的治疗效果。结果表明，治疗组大鼠全肺湿重、干重、胶原蛋白和血清钢蓝蛋白（CP）、过氧化脂质（LPO）、血清及每克肺（干重）的铜（Cu）含量均低于石英对照组，而红细胞超氧化物歧化酶（SOD）、血清及每克肺（干重）锌（Zn）含量则高于石英对照组，有显著性差异（P＜0．05或P＜0．01）。肺纤维化程度治疗组多属Ⅰ级或Ⅱ级，而石英对照组多属Ⅲ级或Ⅱ～Ⅲ级。结果提示，抗矽口服液能显著增加血清和肺组织中的Zn含量，提高抗氧化酶SOD活性，降低血清CU、CP、LPO。说明抗矽口服液对大鼠实验性矽肺有一定疗效。
This article reports the therapeutic effect of anti-silicon oral solution on rat experimental silicosis. The results showed that the wet weight, dry weight, collagen and serum CP, LPO, serum and copper (Cu) content per gram of lung (dry weight) (P <0.05 or P, P <0.05 or P <0.05), while the contents of SOD, serum and per gram of lung (dry weight) zinc were higher than those of the quartz control group <0.01). The degree of pulmonary fibrosis in the treatment group mostly belong to grade Ⅰ or Ⅱ, while the quartz control group mostly belong to grade Ⅲ or Ⅱ ~ Ⅲ grade. The results suggest that anti-silicon oral liquid can significantly increase the serum and lung Zn levels, increased antioxidant enzyme SOD activity, lower serum CU, CP, LPO. Description anti-silicon oral liquid on rat experimental silicosis have a certain effect.